The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an "eye stroke,” is a rare condition...
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an "eye stroke,” is a rare condition...
<iframe src="https://statesidedaily.com/embed/cluster/a7dcbcdcb0e1b836c04aa04e6ff2bec2ef0e55c2" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA warns of rare 'eye stroke' risk from GLP-1 drugs"></iframe>
